Crestone made a significant impact at the ASM Microbe 2025 conference in Los Angeles by presenting groundbreaking research on microbiome analysis. Their presentation, delivered by Dr. Oren Gordon, focused on a Phase 2 clinical trial that compared CRS3123, one of their innovative treatments, to the traditional antibiotic Vancomycin in treating C. difficile infections. This study highlights Crestone’s commitment to advancing biotechnology and developing more effective therapies for challenging infections. Their participation at such a prestigious event underscores their leadership in the biotech field and dedication to improving patient outcomes through cutting-edge research.
For those interested in detailed insights, the IDSE article below offers an in-depth look at their promising research findings.
